News & Updates

Individuals with high alcohol consumption are at increased risk of colorectal cancer (CRC), reports a study, which shows that alcohol intake may trigger colorectal carcinogenesis through mechanisms operating across major molecular pathways for CRC.

Daraxonrasib—an oral, potent RAS(ON) multi-selective, tri-complex inhibitor—demonstrates unprecedented survival benefits in individuals with previously treated metastatic pancreatic adenocarcinoma (mPDAC) in the landmark phase III RASolute 302 study.

In the phase IIb/III EPICS-III study, the dual PPAR-α/γ agonist saroglitazar improves biochemical response (BCR) rates among individuals with primary biliary cholangitis (PBC) who had an inadequate response or intolerance to ursodeoxycholic acid (UDCA).